CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
| Current Price | ₹2,043.80 |
|---|---|
| Market Cap | ₹12,256 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 66.3 |
| Return on Equity | 24.79% |
| 52-Week Range | ₹1,336.60 – ₹2,292.40 |
| Beta (1Y) | 0.27 |
| Dividend Yield | 0.50% |
| Revenue | ₹422 Cr |
|---|---|
| Net Profit | ₹60 Cr |
| EPS (Basic) | ₹9.83 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Pharmaceuticals-100%
Corona Remedies Limited is trading at ₹2,043.80, with a market capitalisation of ₹12,256 Cr.
Corona Remedies Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Corona Remedies Limited has a P/E of 66.3 and a return on equity of 24.79%.
In Q1 FY27, Corona Remedies Limited reported revenue of ₹422 Cr and net profit of ₹60 Cr, with basic EPS of ₹9.83 (consolidated, parsed from the company's exchange filing).